


salbutamol's good



but  
Combined UDVs  
are better

New *Combined*



A convenient solution for greater Oompah in **GOPD**

# THE FIRST EFFECTIVE ONCE DAILY INHALED STEROID



**Pulmicort**  
**Turbohaler 400**  
 BUDESONIDE

***The Once Daily Pulmicort Turbohaler crowd,  
they have a certain air about them***

**Please refer to full data sheet before prescribing**


**Presentation:** Pulmicort Turbohaler 100: 100µg/puff budesonide dry powder inhaler containing 200 actuations. Pulmicort Turbohaler 200: 200µg/puff budesonide dry powder inhaler containing 100 actuations. Pulmicort Turbohaler 400: 400µg/puff budesonide dry powder inhaler containing 50 actuations. **Uses:** Bronchial asthma. **Dosage and administration:** Individualise dose. Adults (including elderly): 200-800µg daily, in divided doses. A once daily dosage regimen of up to 800µg in the evening may be used by patients already controlled on inhaled steroids (e.g. budesonide or beclomethasone) at appropriate administered to be daily. For further information on transfer to once daily dosing see data sheet. Children: 200-800µg daily, in divided doses. A once daily regimen is not recommended for children under

12 years old. **Maintenance use:** lowest possible dose. Brush the teeth and rinse the mouth out with water after each use. **Contra-indications, warnings, etc.:** Contra-indications: Active pulmonary tuberculosis. **Precautions:** Special care is needed in patients with quiescent lung tuberculosis, fungal and viral infections in the airways. Avoid administration during pregnancy. A short course of oral steroids in addition to Pulmicort may be required in patients with excessive mucus in the airway. Inhaled corticosteroids will not usually affect adrenocortical function. A small proportion of patients may experience some systemic effects after long term treatment at high doses. Transfer of patients dependent on oral steroids to treatment with Pulmicort demands special care. See data sheet for further details. **Side-effects:** 1% irritation in the throat, hoarseness and oral candidiasis occur in some patients. Rarely, skin

reactions such as rash may occur. As with other inhaled therapy, the potential for paradoxical bronchospasm should be kept in mind. **Basic NHS price:** Pulmicort Turbohaler 100: 200 actuations: £18.50. Pulmicort Turbohaler 200 (100 actuations): £18.50. Pulmicort Turbohaler 400 (50 actuations): £18.50. **Legal status:** POM. **Product licence nos.:** Pulmicort Turbohaler 100 PL 00170319. Pulmicort Turbohaler 200 PL 00170272. Pulmicort Turbohaler 400 PL 00170271. For further information contact the Product Licence holder: Astra Pharmaceuticals Limited, Home Park, Kings Langley, Herts WD4 8DH. @Pulmicort and Turbohaler are registered trademarks of Astra Pharmaceuticals Limited. Date of preparation: August 1995. TURB 950613

**ASTRA**  
Astra Pharmaceuticals

# "I sleep well"



Twice daily

## SEREVENT

salmeterol xinafoate

### FOR ACTIVE DAYS AND RESTFUL NIGHTS

#### Serevent (salmeterol xinafoate)

##### Abridged Prescribing Information

(Please refer to the full data sheet before prescribing)  
**Uses** Treatment of asthma (including nocturnal and exercise-induced) in patients requiring long-term regular bronchodilator therapy. Patients should normally also be receiving regular and adequate doses of inhaled anti-inflammatory agents, or oral corticosteroids. **Dosage and administration** For inhalation only. *Adults and children 4 years and over:* 50 micrograms twice daily. *Adults only:* More severe cases 100 micrograms twice daily. *Children below 4 years:* Not recommended at present. **Contra-indication** Hypersensitivity. **Precautions** **Steroid therapy:** Serevent is not a replacement for corticosteroids and/or, in children, sodium cromoglycate. Warn patients not to stop or reduce such therapy. **Severe or unstable asthma:** Bronchodilators should not be the only or main treatment. Consider using oral steroids and/or

maximum doses of inhaled corticosteroids. Warn patients to seek medical advice if short-acting bronchodilator use increases or becomes less effective. Treat severe exacerbations in the normal way. **Acute symptoms:** Serevent is not for relief of acute symptoms. A short-acting inhaled bronchodilator is required. **Thyrotoxicosis:** Use with caution. **Drug interactions:** Avoid beta-blockers. **Hypokalaemia:** May occur, particularly in acute severe asthma. It may be potentiated by xanthine derivatives, steroids, diuretics and hypoxia. Monitor serum potassium levels in these situations. **Pregnancy and lactation:** Experience is limited. Balance risks against benefits. **Side effects** Tremor, subjective palpitations and headaches have been reported, but are usually mild and transient. Skin reactions, muscle cramps, non-specific chest pain, local irritation and arthralgia have been reported. Potentially serious hypokalaemia may result from  $\beta_2$ -agonist therapy. **Paradoxical bronchospasm:**

Substitute alternative therapy. **Presentation and Basic NHS cost** *Serevent Diskhaler:* Pack of 14 four-place disk foils, together with a Serevent Diskhaler. 50 micrograms – £29.97. *Serevent Diskhaler refill pack:* Pack of 14 four-place disk foils only – £29.40. *Serevent Inhaler:* 120 actuations per inhaler. 25 micrograms – £28.60. Hospital packs are also available. **Product licence numbers** 0045/0158, 0045/0157.

POM



ALLEN & HANBURY'S

Further information is available on request from:

Allen & Hanburys Limited  
Uxbridge, Middlesex UB11 1BT

Diskhaler and Serevent are trade marks of the  
Glaxo Group of Companies

September 1993

When introducing Serevent in adults we strongly recommend that you do not stop or reduce the dose of corticosteroids. Similarly, in children, do not stop or reduce corticosteroids or sodium cromoglycate.

#### PRESCRIBING INFORMATION

**Presentations:** Pulmicort Respules. (2ml single dose unit ampoules) containing 0.25mg/ml or 0.5mg/ml budesonide in a suspension for nebulisation. **Uses:** Bronchial asthma where use of a pressurised inhaler or dry powder formulation is unsatisfactory or inappropriate. **Dosage and administration:** Dosage schedules: Administer from suitable nebulisers. Dose delivered to the patient varies depending on the nebulising equipment used (see data sheet). Adjust dosage individually. Initially during periods of severe asthma and while reducing or discontinuing oral glucocorticosteroids the recommended dose in adults (including elderly and children 12 years and older) is usually 1-2mg twice daily. In very severe cases the dosage may be further increased. Children 3 months to 12 years: 0.5-1mg twice daily. The maintenance dose should be the lowest dose which keeps the patient symptom-free. Recommended doses are: Adults (including elderly and children 12 years and older): 0.5-1mg twice

daily. Children (3 months to 12 years): 0.25-0.5mg twice daily. For an increased therapeutic effect increase dose of Pulmicort rather than combine treatment with oral corticosteroids because of the lower risk of systemic effects. **Contra-indications, warnings, etc.:** Contra-indications: Hypersensitivity to any of the constituents. Special warnings and precautions: Care is needed in patients with pulmonary tuberculosis and viral infections in the airways. A short course of oral steroids in addition to Pulmicort may be required in patients with excessive mucus in the bronchi. Transfer of patients dependent on oral steroids to Pulmicort demands special care; see data sheet for further details. The nebuliser chamber should be cleaned and dried after every administration. Pulmicort does not affect the ability to drive and use machines. Pulmicort Respules can be mixed with 0.9% saline and with solutions of terbutaline, salbutamol, sodium cromoglycate or ipratropium bromide. **Side-effects:**

Mild irritation in the throat, coughing and hoarseness and oral candidiasis have been reported. In rare cases inhaled drugs may provoke bronchoconstriction in hyperreactive patients. Facial skin should be washed after use of the face mask as irritation can occur. Coughing can usually be prevented by inhaling a  $\beta_2$ -agonist (e.g. terbutaline) 5-10 minutes before inhalation of Pulmicort Respules. Avoid in pregnancy. **Pharmaceutical precautions:** Store below 30°C. Use within 3 months of opening the foil envelope. Protect opened ampoule from light. Use within 12 hours of opening. **Legal status:** POM. **Basic NHS price:** Pulmicort Respules 0.25mg/ml (20 single dose units) £32.00. Pulmicort Respules 0.5mg/ml (20 single dose units) £44.64. **Product licence nos.:** Pulmicort Respules 0.25mg/ml PL 0017/0309. Pulmicort Respules 0.5mg/ml PL 0017/0310. **Name and address of product licence holder:** Astra Pharmaceuticals Ltd., Home Park, Kings Langley, Herts WD4 8DH.



Inspired control you can trust

Astra Pharmaceuticals Ltd.,  
Home Park,  
Kings Langley,  
Herts WD4 8DH.



© Registered Trademark  
Date of preparation: May 1995  
P.Res. 0382

**Pulmicort**<sup>®</sup>  
 **Respules**<sup>®</sup>  
BUDESONIDE

Nebulised Steroid Control


# Baffled by statistics?

All doctors and medical students need a basic understanding of the statistics presented in medical journals and at clinical meetings. *Statistics in Clinical Practice* is a practical, easy to read guide to demystifying statistics which will show you how to interpret data and present statistical information yourself.


- Covers all the basic principles including probability, making conclusions based on statistical results and summarising data.
- Contains realistic clinical examples.
- Assumes only a basic knowledge of mathematics.
- Includes useful questions and answer sections to test yourself.

ISBN 0 7279 0907 X 128 Pages 1995  
 UK £10.95; Overseas £12.95  
 (BMA members £9.95; £12.00)

Available from:  
 BMJ Publishing Group  
 P.O. Box 295, London WC1H 9TE  
 Tel: 0171 383 6185/6245 Fax: 0171 383 6662



# BRITISH LUNG FOUNDATION



Applicants are invited to apply for the following categories of awards for research carried out in the United Kingdom:

## 1. British Lung Foundation Fellowship Grants

These grants are for a specified research worker, for a stated period of up to three years, with an allowance for necessary supporting costs. The specified research worker should have a PhD or medical qualification.

## 2. British Lung Foundation Project Grants

These grants are for a specified project for up to three years duration. Costs may include salaries. Applications can be for any sum of money up to a maximum of £85,000.

The awards are available either to clinical or non-clinical applicants

**Closing date for all applications 1st March 1996**

Application forms are available from  
**BRITISH LUNG FOUNDATION**  
 78 Hatton Garden, London EC1N 8JR  
 Tel: 0171 831 5831

PLEASE QUOTE REFERENCE THX/96

The British Lung Foundation is a charity funding research into the prevention, diagnosis and treatment of all lung diseases.

# ABC OF SLEEP DISORDERS

ro and his colleagues have  
 tulated on previous  
 ort and wide  
 ves a wide audi



This comprehensive, well illustrated guide provides a detailed introduction to all aspects of sleep, sleep disorders, and their associations with illness. Topics covered include:  
 Function of sleep; Insomnia;  
 Daytime sleepiness; Sleep apnoea;  
 Circadian rhythms; Dreams and medical illness; Medico-legal aspects.

AVAILABLE NOW PLEASE SEND ME  COPY(IES) AND A BMJ PUBLISHING GROUP CATALOGUE  BOOK TOKENS ACCEPTED (UK ONLY)

NAME

I ENCLOSE A CHEQUE FOR  
 (MADE PAYABLE TO BRITISH MEDICAL JOURNAL)

ADDRESS

PLEASE DEBIT MY CREDIT CARD VISA AMEX MASTERCARD

POSTCODE

CARD NO.

EXPIRY DATE /

BMA MEMBERSHIP NO.

SIGNATURE

Available from BMJ Publishing Group, PO Box 295, London WC1H 9TE (telephone 0171 383 6185/6245), medical booksellers or the BMJ Bookshop in BMA House.

# Turbohaler Kids have a certain air about them



**Presentation:** Bricanyl Turbohaler: Dry powder inhaler delivering 0.5 mg terbutaline sulphate per actuation. **Uses:** Relief and prevention of bronchospasm in bronchial asthma and bronchopulmonary disorders in which bronchospasm or reversible airways obstruction is a complicating factor.

**Dosage and administration:** Adults and children (including elderly): One inhalation (0.5 mg) as required. Not more than 4 inhalations/day. **Contra-indications, warnings, etc.:** Contra-indications: Sensitivity to terbutaline sulphate. **Precautions:** Care should be taken in patients with myocardial insufficiency or thyrotoxicosis. Additional blood glucose measurements are initially recommended in diabetic patients. If treatment becomes less effective or shorter acting, the patient's general condition should be reviewed. Do not use in patients with hypertrophic cardiomyopathy. Potentially serious hypokalaemia may result from  $\beta_2$ -agonist therapy. Administer with caution during the first trimester of pregnancy. Do not administer concurrently with non-selective  $\beta$ -blockers. Use with caution with other sympathomimetics. Side effects: Tinnitus, tremor and palpitations are all characteristic of

sympathomimetic amines. A few patients feel tense. **Basic NHS price:** Bricanyl Turbohaler (100 doses) £7.96. **Legal category:** POM. **Product licence no.:** PL 0017/02241.

**Presentation:** Pulmicort Turbohaler 100: 100µg/puff budesonide dry powder inhaler containing 200 actuations. Pulmicort Turbohaler 200: 200µg/puff budesonide dry powder inhaler containing 100 actuations. Pulmicort Turbohaler 400: 400µg/puff budesonide dry powder inhaler containing 50 actuations. **Uses:** Bronchial asthma. **Dosage and administration:** Individualise dose. Adults (including elderly): 200-1600µg daily in divided doses. Children: 200-800µg daily in divided doses. Maintenance: Use lowest possible dose. Brush the teeth and rinse the mouth out with water after each use. **Contra-indications, warnings, etc.:** Contra-indications: Active pulmonary tuberculosis. **Precautions:** Special care is needed in patients with quiescent lung tuberculosis, fungal and viral infections in the airways. Avoid administration during menstruation. A short course of oral steroids in addition to

Pulmicort may be required in patients with excessive mucus in the bronchi. Transfer of patients dependent on oral steroids to treatment with Pulmicort demands special care. See data sheet for further details. **Side-effects:** Mild irritation in the throat, hoarseness and oral candidiasis occur in some patients. **Basic NHS price:** Pulmicort Turbohaler 100 (200 actuations) £18.50. Pulmicort Turbohaler 200 (100 actuations) £18.50. Pulmicort Turbohaler 400 (50 actuations) £18.50. **Legal status:** POM. **Product licence nos.:** Pulmicort Turbohaler 100 PL 0017/0319. Pulmicort Turbohaler 200 PL 0017/0272. Pulmicort Turbohaler 400 PL 0017/0271.

For further information contact the Product Licence holder: Astra Pharmaceuticals Limited, Home Park, Kings Langley, Herts WD4 8JH. ©Pulmicort, Bricanyl and Turbohaler are registered trademarks of Astra Pharmaceuticals Limited. Date of preparation: August, 1995. T188 05C575R

**Bricanyl®**  
Turbohaler®  
TERBUTALINE SULPHATE

**Pulmicort®**  
Turbohaler®  
BUDESONIDE

DESIGNED FOR EFFICIENCY

